Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
——

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.62B+62.8%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Supernus Pharmaceuticals (SUPN) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $254K in Q1 2026.
How has Supernus Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
Supernus Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 46.8% year-over-year, from $173K to $254K.
What is the long-term trend for Supernus Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -8.0% compound annual growth rate (CAGR), from $41K to $27K.